Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINKLE selumetinib granules study in young children with NF1-related plexiform neurofibromas
NL-OMON56067Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by AstraZeneca. Primary endpoints: Selumetinib AUC0-12 and Safety and tolerability. Started Oct 2022; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NL-OMON56067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56067.